Académique Documents
Professionnel Documents
Culture Documents
INTRODUCTION
About 85% of stomach cancers are Adenocarcinomas which may be diffuse type or intestinal
type. Remaining 15% are Lymphomas, Gastrointestinal stromal tumors (GIST) and
Leiomyosarcomas. Usually 30% of Gastric cancers originate in distal stomach; 37% in proximal
one third of stomach; 13% involve the entire stomach.
NORMAL RANGE
<6U/mL
CLINICAL USE
An aid in the management of Gastric cancer patients
Monitor the course of disease and predict recurrence in patients with Gastric
carcinoma
Useful in detecting residual tumor
Page 1 of 3
INTERPRETATION
Increased Levels
Gastric carcinoma
Ovarian carcinoma
Benign diseases – Pancreatitis, Cirrhosis, Pulmonary disease, Rheumatic conditions,
Ovarian cysts, Benign breast disease, Benign gastro-intestinal disorders
Detection of Germ line mutation in E-Cadherin gene (CDH1) in young asymptomatic carriers has
been linked to a high incidence of occult diffuse type gastric cancer
Detection of KRAS mutations is indicative of early event in intestinal type Gastric cancer
Cyclin E overexpression correlates with progression from dysplasia
LABORATORY DIAGNOSIS
LIMITATIONS
Page 2 of 3
The assay value should be used in conjunction with findings from clinical evaluation and
other radiographic diagnostic procedures.
Patients receiving Biotin therapy in high doses should not be tested for at least 8 hours
after the last dose.
Page 3 of 3